Correspondence 0001213900-26-057419 from Scinai Immunotherapeutics Ltd. (SCNI)
Scinai Immunotherapeutics Ltd.
Date: May 15, 2026 · CIK: 0001611747 · Accession: 0001213900-26-057419
AI Filing Summary & Sentiment
Reasoning
Letter
Scinai Immunotherapeutics Ltd.
Jerusalem BioPark, 2 nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
May 15, 2026
VIA EDGAR
United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Attention: Doris Stacey Gama
Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS Scinai Immunotherapeutics Ltd. (CIK No. 0001611747) Registration Statement on Form F-3 (File No. 333- 295698 )
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Scinai Immunotherapeutics Ltd. (the "Company") hereby requests acceleration of the effective date of its Registration Statement on Form F-3 (File No. 333- 295698) so that it will be declared effective at 9:00 a.m., Eastern Time, on May 19, 2026, or as soon thereafter as is practicable.
Should you have any questions regarding this letter, please do not hesitate to contact Perry Wildes, Adv., at +972 (3) 607-4444 or perry.wildes@goldfarb.com, of Goldfarb Gross Seligman & Co., counsel to the Company.
Sincerely,
Scinai Immunotherapeutics Ltd.
Show Raw Text
CORRESP 1 filename1.htm Scinai Immunotherapeutics Ltd. Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel May 15, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Stacey Gama Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS Scinai Immunotherapeutics Ltd. (CIK No. 0001611747) Registration Statement on Form F-3 (File No. 333- 295698 ) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Scinai Immunotherapeutics Ltd. (the "Company") hereby requests acceleration of the effective date of its Registration Statement on Form F-3 (File No. 333- 295698) so that it will be declared effective at 9:00 a.m., Eastern Time, on May 19, 2026, or as soon thereafter as is practicable. Should you have any questions regarding this letter, please do not hesitate to contact Perry Wildes, Adv., at +972 (3) 607-4444 or perry.wildes@goldfarb.com, of Goldfarb Gross Seligman & Co., counsel to the Company. Sincerely, Scinai Immunotherapeutics Ltd. By: /s/ Amir Reichman Amir Reichman Chief Executive Officer